Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

Item

http://www.wikidata.org/entity/Q34632080

Q34632080

about

Clinical management of localized colon cancer with capecitabine The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Optimizing adjuvant therapy and survivorship care of stage III colon cancer.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised co Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma.Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.The localisation of cancer in the sigmoid, rectum or rectosigmoid junction using endoscopy or radiology-What is the most accurate method?A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.From Evidence-based Medicine to Personalized Medicine Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.Current opinion on optimal treatment for colorectal cancer.Real-world resource use and costs of adjuvant treatment for stage III colon cancer.Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.Effects of gender on capecitabine toxicity in colorectal cancer.Combination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis.Oral versus intravenous fluoropyrimidines for colorectal cancer.Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer.Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting.The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report.Clinicopathologic features and prognostic factors for patients with colorectal cancer who are 75 years and older.Delivery of adjuvant chemotherapy among stage III colon cancer patients at a public versus private hospital in New York City.Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiother Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer.

P2860

Q24611758-5F514A0D-16D4-443D-B8A2-B48782F53CFB Q27852108-D0F7BCA4-B872-412A-B79F-AC759976102A Q30244769-5CF8C45A-9092-42A4-AB50-6AAC90ACB90E Q30249616-F623D164-3240-405E-984C-AF184EB39662 Q30316930-DC738EA4-2F67-45FD-B8A7-392EF46DC85B Q33432931-72452158-2D03-4A7B-AD72-A22376770EBE Q33831963-99A8578A-B451-4B9F-BA17-37E413DC30C8 Q33840352-F65A7098-36CD-4B53-9B53-33354B78FC2C Q34484336-6E7421DF-7F50-4A88-A394-0DC0111CF36A Q34978436-1084C6C3-23E7-4164-8E0F-B13F589B151E Q35625752-07448D57-DD6C-4DDD-9414-A29DEE83AACF Q35733020-8A2054CA-9FE8-4B1E-912A-68AAD35B8B65 Q35920292-30FC64AF-41D5-4532-BF3B-273B0AA6ED87 Q36084353-6A68781D-BD39-4F6D-981F-095DA7B504BC Q36239072-41829814-814C-4786-BE83-9F4119190546 Q36303226-348111B8-A09D-4E5A-BC89-C296682B5215 Q36385665-75104B5C-CFEA-4A57-A09A-E720697C60F5 Q36403027-5CFF1459-928F-4F4C-A8BE-0349C61FCB31 Q36429095-425AF304-3C77-46AF-A722-FBC35BAFCA0B Q36506987-1FEA58C2-46AD-4BD7-B0BE-6BBB15894971 Q36750713-9198BDAC-EE8E-4EDB-A9BA-47F461E9CCA2 Q37697523-31317276-5947-4323-A9AD-B25F352CA6CB Q38101612-D3E33E5E-F28F-4D5D-A62C-37447AF8145E Q38174218-DDE05A72-EBBF-40CF-BE73-BBBC7FE75DA0 Q38228522-46B0F824-DF5D-442D-9FED-DD6225A177FC Q38499473-17A373E7-62BB-47D8-B063-5C2FF40C0B07 Q38644154-23733D84-CC11-4CE4-BA1B-1479EC31EDC9 Q38650502-18BD3F73-E666-4E8F-BE4D-50700FFCA8DF Q38683073-ACB7F45A-0513-4458-8F62-545C0AAEE7F3 Q38707832-AD39EA94-C84F-439C-87A2-02514B572EDD Q38872765-1080AE54-0FCD-4B3A-823F-378222A30B26 Q39233316-B1928C3C-47F3-4440-B161-FEF710ECDE56 Q40586852-7F9E84C4-E4F9-4961-9711-DF43C8E8D538 Q40997435-69715EE3-E1A8-4582-A162-8D457B21BE68 Q41040753-A762BF60-3FB0-4467-A99D-4F75F0A96256 Q47156783-F67FB85C-182B-4454-A74D-35659894B1AB Q47776943-44E1C98E-B005-4E74-AA29-6AF41AD92591 Q48017326-972ABF2B-F973-4B63-96E2-A5586CC55B5A Q53662723-1368A579-5EBD-4680-B257-01DE5EEB8603 Q55007703-3C7206BC-A67A-47C7-A0E7-405B81680FB1

P2860

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

Item

http://www.wikidata.org/entity/Q34632080

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu